Not provided
Not provided
Not provided
Not provided
interrupted early due to the drastic reduction in the number of cases
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Starting an early home management and monitoring of patients with suspected or confirmed COVID-19 to ensure a rapid and adequate transfer to hospital care.
Assess the feasibility of home monitoring in a pilot study to possibly extend it to a larger scale.
The study will include adult patients with suspected or confirmed COVID-19 for whom home care is considered appropriate.
Trained health workers will conduct home care monitoring of pulmonary performance using oximetry, Quick Walk Test and Single Breath Count.
Monitoring will be done daily until disappearance of symptoms or hospitalization which will be requested by health workers or study coordination board on the basis of the monitoring results (blood oxygen level SpO2< 90% OR SpO2> 90% with desaturation index of at least 5% at Quick Walk Test)
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| home care with active monitoring | Experimental | home care with active monitoring conducted by health workers with daily visit to patients. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| home care monitoring | Other | home care active monitoring of patients with suspected of confirmed COVID-19 |
|
| Measure | Description | Time Frame |
|---|---|---|
| SpO2 at hospital entry | Peripheral blood saturation measured on arrival to the hospital | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| in-hospital mortality | death during hospitalization | 30 days |
| need of intubation | need of intubation | 30 days |
Not provided
Inclusion criteria:
adult patients with suspected or confirmed COVID-19 for whom home care is considered appropriate.
Exclusion criteria: physical, mental or temporary impairments that preclude the conduction of the test
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Guido Bertolini, MD | Mario Negri Institute for Pharmacological Research | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Asl Alessandria | Casale Monferrato | Alessandria | Italy |
data will be available from the study sponsor upon legitimate request
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
single arm, open label trial on active home monitoring strategy
Not provided
Not provided
Not provided
Not provided
| Percentage of hospitalized patients among those with recommendation of hospitalization | To evaluate the feasibility of active monitoring, we will consider the percentage of patients who will be actually hospitalized within 24 hours after the recommendation of hospitalization | 30 days |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |